BH3 mimetic drugs may be useful to treat acute lymphoblastic leukemia
(ALL) but the sensitivity of primary tumor cells has not been fully evaluated.
Here B-lineage ALL cell cultures derived from a set of primary tumors were
studied with respect to sensitivity to the BH3 mimetics ABT-263 and ABT-199 and
to Bcl-2 dependence and function. These ALL cells each expressed high levels of
Bcl-2 and exhibited great sensitivity to ABT-263 and ABT-199, which induced
rapid apoptotic cell death. BH3 profiling indicated that the ALL cultures were
Bcl-2 dependent. Co-immunoprecipitation studies revealed a multi-faceted role
for Bcl-2 in binding pro-apoptotic partners including Bax, Bak, Bik and Bim.
ABT-263 disrupted Bcl-2:Bim interaction in cells. Mcl-1 overexpression rendered
ALL cells resistant to ABT-263 and ABT-199 with Mcl-1 assuming the role of Bcl-2
in binding Bim. Freshly isolated pediatric ALL blasts also expressed high levels
of Bcl-2 and exhibited high sensitivity to Bcl-2 inhibition by the BH3 mimetic
compounds. Overall our results showed that primary ALL cultures were both more
sensitive to BH3 mimetics and more uniform in their response than established
ALL cell lines which have been evaluated previously. Further, the primary cell
model characterized here offers a powerful system for preclinical testing of
novel drugs and drug combinations to treat ALL.
SummaryMinor histocompatibility (mH) antigens appear to play a major role in bone marrow transplantation (BMT) using HLA identical donors. Previously, we reported the isolation of major histocompatibility complex (MHC)-restricted mH antigen-specific cytotoxic T lymphocytes (CTL) from patients with graft-vs .-host disease or rejection after HLA-identical BMT We have demonstrated that mH antigens can be recognized on hematopoietic progenitor cells, and residual recipient CTL specific for mH antigens expressed on donor hematopoietic progenitor cells may be responsible for graft rejection in spite of intensive conditioning regimens in HLA-identical BMT. Here, we investigated whether mH antigen-specific CTL directed against the mH antigens HA-1 to HA-5 and the male-specific antigen H-Y were capable of antigen-specific inhibition of in vitro growth of clonogenic leukemic precursor cells. We demonstrate that mH antigen-specific CTL against all mH antigens tested can lyse freshly obtained myeloid leukemic cells, that these mH antigenspecific CTL can inhibit their clonogenic leukemic growth in vitro, and that this recognition is MHC restricted . We illustrate that leukemic (precursor) cells can escape elimination by mH antigen-specific CTL by impaired expression of the relevant MHC restriction molecule. We suggest that mH antigen-specific MHC-restricted CTL may be involved in vivo in the graft-vs .-leukemia reactivity after BMT
Clinical studies indicated an enhanced antileukemic effect of allogeneic bone marrow transplantation (BMT), as compared with autologous BMT. After allogeneic HLA-identical BMT, donor-derived cytotoxic T lymphocytes (CTLs) directed at minor histocompatibility (mH) antigens on the recipients, tissues can be shown. To evaluate the antileukemic reactivity of mH antigen-specific CTLs, we analyzed the expression of mH antigens on circulating lymphocytic and myeloid leukemic cells. We show that the defined mH specificities HA-1 through HA-5 and H-Y are present on leukemic cells, indicating that mH antigen- specific CTLs are capable of HLA class I-restricted antigen-specific lysis of leukemic cells. Compared with interleukin-2-stimulated normal lymphocytes, leukemic cells of lymphocytic origin are less susceptible to T-cell-mediated cytotoxicity by the HA-2 mH antigen-specific CTL and the anti-HLA-A2 CTL clone. A possible explanation for this phenomenon is impaired expression of the LFA-1 adhesion molecule. Our study suggests that mH antigen-specific HLA class I-restricted CD8+ CTLs may be involved in the graft-versus-leukemia reactivity after allogeneic BMT.
Pure interleukin 1 (IL 1) was found to stimulate established human bone marrow stromal layers in long-term culture to produce colony- stimulating activity (CSA). Maximal concentrations in the culture medium were reached 24 hours after a single IL 1 pulse. The effect could be neutralized by a specific rabbit anti-IL 1 antiserum. Stromal layers, once stimulated by IL 1, continued to release CSA into the culture medium in the absence of exogenous IL 1. A second IL 1 pulse induced CSA release in an identical manner, as did the primary stimulation, indicating that the CSA released was actively produced. Using specific immunologic assays, both granulocyte colony-stimulating factor (G-CSF) and macrophage CSF (M-CSF) could be identified in the culture supernatants, and production of both factors was inducible by IL 1. Shortly after initiation of the long-term marrow cultures “spontaneous” G-CSF and M-CSF release occurred. The release of G-CSF diminished following addition of the anti-IL 1 antiserum, indicating that endogenous production of IL 1 by stromal cells had contributed to this effect. These results further support the role of IL 1 as an important modulator of CSF production by cells of the hematopoietic microenvironment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.